PathoGenesis Corp.

PathoGenesis Corporation is dedicated to improving human health and quality of life. We develop and market novel drugs to treat serious, chronic infectious diseases where there is a significant need for improved therapy. More specifically, we focus on products and technologies-such as inhaled antibiotics-that bring innovative solutions to unmet medical needs. To realize our goals, we strive to create an environment that fosters innovation. We will measure our success in terms of improving the health of patients, providing personal growth to our staff, and creating long-term value for our shareholders. Our first drug, TOBI® (tobramycin solution for inhalation), treats people with cystic fibrosis who have a lung infection caused by Pseudomonas aeruginosa bacteria. This life-long lung infection causes progressive destruction of lung tissue. In addition, periodic flare-ups of pseudomonal infections cause life-threatening episodes and hospitalization. People with cystic fibrosis have an average life expectancy of 32 years.

Activity:

- Manufacturing
- Sales & Distribution

Product / Technology type(s) covered:

- Pharmaceuticals / Therapeutics
- Technology

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active: North America , Europe

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: